NSCLC Lucanix Vaccine for Non Small Cell Lung Cancer Frequently Asked Questions
http://www.ircofca.com 1-877-680-IRCC (4722) Innovative Research Center of California (IRCC) is an independent, dedicated research facility that specializes in new treatments for Oncology and Medicine. IRCC's team of investigators and research coordinators have decades of experience performing clinical investigative trials. IRCC's mission is to assist in advancing science and the development of novel treatments, while always keeping the study volunteer's best interest the primary focus.
IRCC is actively working with NovaRx to enroll patients in a research study of Lucanix, an investigational lung cancer vaccine. This vaccine is currently in Phase III trials. The entry criteria for this FDA approved trial are strict and there will be a number of patients who won't qualify for the study. In an effort to increase availability to Lucanix, IRCC has been chosen by NovaRx to provide an "expanded access" trial with Lucanix to a limited number of qualified research participants. Only individuals who do not qualify for the Phase III trial will be eligible for screening for the expanded access protocol.
-
Category
No comments found